Lonza Group Ltd
O6Z
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
Basel4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
19,299
Stocks News & Analysis
stocks
Finding value in the Aussie mining sector
Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
stocks
Strong start to the year for cheap ASX share
Investors are ignoring a strong long-term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,793.40 | 29.00 | 0.33% |
| CAC 40 | 7,989.44 | 8.37 | 0.10% |
| DAX 40 | 23,091.87 | 186.98 | -0.80% |
| Dow JONES (US) | 46,245.41 | 493.15 | 1.08% |
| FTSE 100 | 9,531.01 | 3.36 | 0.04% |
| HKSE | 25,578.88 | 358.86 | 1.42% |
| NASDAQ | 22,273.08 | 195.03 | 0.88% |
| Nikkei 225 | 48,625.88 | 1,198.06 | -2.40% |
| NZX 50 Index | 13,499.85 | 80.45 | 0.60% |
| S&P 500 | 6,602.99 | 64.23 | 0.98% |
| S&P/ASX 200 | 8,517.10 | 25.40 | 0.30% |
| SSE Composite Index | 3,821.68 | 13.21 | -0.34% |